| WM |
Report |
Revenue |
IN-LINE |
pred ~$6.72B vs. cons $6.707B |
MEDIUM |
| WM |
Report |
Operating EBITDA |
IN-LINE |
pred ~$2.04B vs. cons $2.032B |
MEDIUM |
| WM |
Report |
Core price |
IN-LINE |
pred ~6.10% vs. cons 6.05% |
MEDIUM |
| WM |
Guide |
Free cash flow (FY 2026) |
LOWER |
guide ~$3.750-$3.850B vs. cons $3.868B |
MEDIUM |
| WM |
Guide |
Operating EBITDA (FY 2026) |
UNCHANGED |
guide maintain existing range - UNVERIFIED vs. cons $8.202B |
LOW |
| WM |
Guide |
Margin / volume commentary (2H 2026) |
UNCHANGED |
guide Q2 muted, H2 lift; consensus UNVERIFIED |
LOW |
| WM |
Return |
Day-1 residual (stock − beta × S&P 500) |
-1.5% |
— |
LOW |
| WM |
Return |
5-day cumulative residual |
-2.5% (FOLLOW-THROUGH) |
FOLLOW-THROUGH — routine result does not clear the elevated setup |
LOW |